Humanigen Inc. (HGEN)
| Market Cap | 1.16B |
| Revenue (ttm) | 798,000 |
| Net Income (ttm) | -152.64M |
| Shares Out | 52.66M |
| EPS (ttm) | -3.44 |
| PE Ratio | n/a |
| Forward PE | 12.38 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $19.68 |
| Previous Close | $20.06 |
| Change ($) | -0.38 |
| Change (%) | -1.89% |
| Day's Open | 19.74 |
| Day's Range | 18.88 - 19.96 |
| Day's Volume | 987,965 |
| 52-Week Range | 7.75 - 29.20 |
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it has initiated a rolling review submission for Marketing Authorization (MA) by the MHRA for its lead drug candidate, lenzilumab
While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces it will present at the 2021 LD Micro Invitational XI
One is growing revenue. And the other may soon launch its first product.
Humanigen Inc (NASDAQ: HGEN) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for lenzilumab to treat patients hospitalized with COVID-19. The application is based on po...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces submission of application to the FDA requesting Emergency Use Authorization for lenzilumab
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces that granulocyte macrophage-colony stimulating factor gene-edited CAR-T data will be presented at the ISCT 2021 Annual Meeting
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
Humanigen Inc (NASDAQ: HGEN) and Chime Biologics, contract development and manufacturing organization (CDMO), have entered into a manufacturing services agreement to produce Humanigen's lenzilumab bulk ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen and Chime Biologics today announced that they have entered into a manufacturing services agreement.
Humanigen Inc (NASDAQ: HGEN) is prepping its COVID-19 drug lenzilumab for an emergency use authorization with the FDA before the month's end. According to its Q1 financial report out Thursday after-hour...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. today reported financial results for the first quarter ending March 31, 2021 and provided a regulatory update on lenzilumab.
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Humanigen Inc. (NASDAQ: HGEN) shares made gains Wednesday following the publication of results from a Phase 3 randomized double-blind placebo-controlled study.
Detailed results from a late-stage study of the company's lead candidate were published online.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer.
They're both innovating in attractive areas where there's no competition on the radar.
New coronavirus projects make them easy to hype, but they could face strong headwinds soon.
Humanigen Inc (NASDAQ: HGEN) has announced data from the Phase 1b portion of the ZUMA-19 trial evaluating its lead candidate lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (D...
BURLINGAME, Calif.--(BUSINESS WIRE)--Positive data announced from the Phase 1b portion of ZUMA-19 evaluating the efficacy and safety of lenzilumab in patients treated with CAR-T in DLBCL.
They're approaching the treatment-race finish line.
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and l...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces positive results from the Phase 1 safety and bioimaging trial of ifabotuzumab.
It's a definite maybe.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it completed its underwritten public offering of common stock.
The company announced the pricing of a secondary stock offering.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine ...
Humanigen Inc. (NASDAQ: HGEN) share rallied Monday amid positive Phase 3 data demonstrating Lenzilumab TM achieved its primary endpoint. The drug improves survival without the need for mechanical ventil...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock.
The company's investigational coronavirus treatment could hit the market soon.
Shares of HGEN stock are soaring after the firm said its drug results show improved survival for Covid-19 patients without a ventilator. The post HGEN Stock: Why Covid-19 Play Humanigen Is Skyrocketing ...
Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.
Humanigen Inc (NASDAQ: HGEN) has reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19. The 520-patient study demonstrated that ...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces positive topline results from its Phase 3 clinical trial.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. announced today that its board of directors has scheduled the corporation's 2021 Annual Meeting of Shareholders for June 17, 2021.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. has obtained a term loan facility from Hercules Capital.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. reports financial results for the year ending December 31, 2020 and announces objectives for 2021.
Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen awarded two patents, expanding their anti-GM-CSF patent portfolio.
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces the election of Dr. Dale Chappell, the Company's chief scientific officer, to serve as a board director of the Company.
BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered ...
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine s...
About HGEN
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies t... [Read more...]
| Industry Biotechnology | IPO Date Jan 31, 2013 |
| CEO Cameron Durrant | Employees 10 |
| Stock Exchange NASDAQ | Ticker Symbol HGEN |
Analyst Forecasts
According to 6 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 34.88, which is an increase of 77.24% from the latest price.